1. Scrip
  2. >>Business

Venture Funding Deals, July – August 2016

 
• By Deanna Kamienski, Beth Allan, Maureen Riordan, Steven Muntner, and Amanda Micklus

Ambrx, Arcus, Cleave Biosciences, InflaRx, MonoSol Rx, Nevakar and Tioma Therapeutics were among firms raising more than $30m in venture funding in July and August. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive review of emerging biopharmaceutical companies that have received venture funding during the past two months.

Coins

Ambrx Inc. (protein therapeutics known as bio-conjugates) raised $45m in a late-stage financing round led by Apricot Capital and Northeast Securities Prosperity Healthcare Fund. (Also see "VC Roundup: Cleave Raises $37m To Maintain Phase I Momentum, Plus $233.5m In Recent Financings" - Scrip, 10 August, 2016.) Sinopharm Capital, Humanwell Healthcare Fund, and existing investors Fosun Pharma, HOPU Investments, and Everbright Limited Healthcare Fund also participated. The company will use the funds to further develop its Phase I asset ARX788 along with its pipeline of ADC candidates and lead immuno-oncology program CD3-folate. After withdrawing from its planned IPO in June 2014, the company was acquired by a consortium consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group Co. Ltd., HOPU Investments, China Everbright Ltd.'s CEL Healthcare Fund, and WuXi PharmaTech Inc. (Aug.) [See Deal]

Arcus Biosciences Inc. (immuno-oncology) raised $70m through its oversubscribed Series B round. The company's initial targeted amount was $50m....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

More from Scrip

Citeline Japan Awards 2025 - Enter Now!

 
• By Ian Haydock and Lisa Takagi

The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get those submissions in by this date. Sponsorship opportunities and tables for the event are also available.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.